ArticleJournal of clinical microbiology2003
Diagnostic potential of parechovirus capsid proteins.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Isolation and characterization of phage display-derived scFv antibodies against human parechovirus 1 VP0 protein.Scientific reports · 2022Article
- Review
- Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.Clinical microbiology reviews · 2018Review
- Strain-dependent neutralization reveals antigenic variation of human parechovirus 3.Scientific reports · 2017Article
- The Structure of Human Parechovirus 1 Reveals an Association of the RNA Genome with the Capsid.Journal of virology · 2016Article
- Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.Journal of virology · 2015Article
- Human Memory B Cells Producing Potent Cross-Neutralizing Antibodies against Human Parechovirus: Implications for Prevalence, Treatment, and Diagnosis.Journal of virology · 2015Article
- Growth characteristics of human parechovirus 1 to 6 on different cell lines and cross- neutralization of human parechovirus antibodies: a comparison of the cytopathic effect and real time PCR.Virology journal · 2013Article
- Human parechovirus genotypes -10, -13 and -15 in Pakistani children with acute dehydrating gastroenteritis.PloS one · 2013Article
- Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains.PloS one · 2013Article
- Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein.Virology journal · 2012Article
- Several recombinant capsid proteins of equine rhinitis a virus show potential as diagnostic antigens.Clinical and diagnostic laboratory immunology · 2005Article
- Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome.Clinical and diagnostic laboratory immunology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study humoral and cellular immunity against human parechovirus type 1 (HPEV1), the viral capsid proteins VP0, VP1, and VP3 were expressed and purified as glutathione S-transferase (GST)-tagged recombinant proteins. The fusion proteins were used to raise antisera in rabbits. VP0 and VP1 antisera specifically detected HPEV1-infected cells in culture by immunoperoxidase staining and immunofluorescence. Furthermore, antisera against the VP0 and VP1 proteins had neutralizing effects against HPEV1 infection. When the HPEV1 antibody titers of 20 adults and 55 children were determined by a microneutralization test, the prevalence of HPEV1 antibodies in the adult population was 96%, while 50% of children were seropositive. Selected sera were used to evaluate HPEV1 fusion proteins as antigens in an enzyme immunoassay. The VP3 capsid protein appeared to be suitable for the purpose, with specificity of 100% and sensitivity of 96% compared to the neutralization test. Furthermore, T-cell responses to the purified HPEV1 and HPEV1 capsid fusion proteins were studied in 20 adults. Sixty percent of the subjects had T-cell proliferation responses to purified HPEV1, and 90% of the subjects also had positive T-cell responses to at least one of the GST capsid proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.